Trial Profile
Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Belatacept (Primary) ; Sirolimus (Primary) ; Mesenchymal stem cell therapy; Mycophenolate mofetil; Mycophenolate sodium; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TEACH
- 08 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2023 Planned number of patients changed from 6 to 8.
- 30 Jan 2023 Status changed from active, no longer recruiting to recruiting.